Securities Investigation Launched Into Cellebrite's Guidance Cut
CLBT is trading near its 52-week low of $9.58 (14% above the low).
Summary
SueWallSt, powered by Levi & Korsinsky LLP, has opened an investigation into potential securities law violations by Cellebrite DI Ltd. The probe centers on whether management adequately disclosed the conditions underlying its 2026 outlook before the August 13 guidance cut that sent shares down 31%. The firm specifically flags a discrepancy: on the May 14 Q1 call, CFO David Barter guided Q2 ARR to $510-513 million, but actual Q2 ARR came in at $507.8 million. This follows the company's Q2 revenue miss of approximately $131.1 million and reduced FY26 ARR and revenue guidance, alongside the CEO transition to Shiven Ramji. The investigation adds a legal overhang to an already battered stock trading near its 52-week low.
At the time of this announcement, CLBT was trading at $10.92 on NASDAQ in the Technology sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $9.58 to $19.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.